Core Viewpoint - The company announces a price adjustment for its anti-tumor drug, Doxorubicin Liposome Injection, due to its inclusion in the national centralized procurement directory, which will lead to a significant reduction in sales revenue for 2025 [4][6]. Group 1: Drug Overview - The drug, Doxorubicin Liposome Injection, was launched in August 2009 and is the first domestic generic version of Doxil/Caelyx, utilizing advanced liposome technology for passive targeting [2]. - In 2024, the drug generated approximately RMB 210 million in sales, accounting for 29% of the company's total revenue [2]. - The drug is primarily used for treating Kaposi's sarcoma related to AIDS, as well as multiple myeloma, breast cancer, and ovarian cancer [2][3]. Group 2: Reasons for Price Adjustment - The drug has been included in the national centralized procurement list for the first time in 2024, with the execution period lasting until December 31, 2027 [4]. - The company plans to gradually reduce the market retail price by no less than 35% starting from May 1, 2025, in response to the new procurement rules and market competition [4]. Group 3: Company Measures - The company will maintain long-term cooperation with existing suppliers and ensure stability in its production and quality control processes [5]. - It will optimize its marketing network and focus on developing new markets, particularly in private and profit-oriented medical institutions [5]. - The company aims to increase R&D investment to ensure continuous revenue contributions from other products while accelerating the commercialization of new products in advantageous areas [5]. Group 4: Impact of Price Adjustment - The price adjustment is expected to adversely affect the sales revenue of Doxorubicin Liposome Injection in the second quarter of 2025 and beyond, with an anticipated decline of over 50% in annual sales revenue [6]. - This decline may lead to a risk of single-product losses for the drug in 2025 [6].

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]

Core Viewpoint - Several listed companies in the Shanghai and Shenzhen markets have announced significant updates, including stock suspensions, name changes, and financial adjustments, which may present both opportunities and risks for investors [4][5][8][10]. Group 1: Stock Suspension and Changes - ST Xinchao will suspend its stock from May 6, 2025, due to the inability to disclose audited financial reports within the legal timeframe, with a risk of delisting if reports are not provided within two months [4]. - Wolong Real Estate plans to change its stock name to "Wolong New Energy" to align with national carbon neutrality policies and explore new profit growth areas [5]. Group 2: Financial and Operational Updates - Dongzhu Ecology clarified that it holds only a 10% stake in Dilos AI Technology and has no substantial business cooperation with it, indicating potential uncertainties in future performance [6][7]. - Haitian Flavor Industry has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue up to 710.52 million shares for overseas listing, though uncertainties remain [8]. - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection, which generated approximately RMB 210 million in sales in 2024, accounting for 29% of total revenue, potentially leading to losses in 2025 [10]. Group 3: Shareholding and Financing Activities - Jiangbolong's major shareholder, the National Integrated Circuit Industry Investment Fund, plans to reduce its stake by up to 1% through market transactions between May 27 and August 26, 2025, without affecting control [12][13]. - Cambrian Technology intends to raise no more than RMB 4.98 billion through a private placement to fund projects related to large model chip and software platforms and to supplement working capital [14]. - Jinzhen Co. plans to sell up to 5 million shares from its repurchased stock, which amounts to 50% of the total repurchased shares, to maintain company value and shareholder interests [15]. Group 4: Major Contracts and Procurement Wins - Aolaide's subsidiary signed a sales contract worth RMB 655 million with Chengdu BOE Display Technology, expected to positively impact the company's performance in 2025 and 2026 [16]. - Tongguang Cable is a candidate for two procurement projects from the State Grid Corporation, with a total expected bid amount of RMB 142 million, representing approximately 5.49% of the company's total revenue for 2024 [17].

经本公司审慎研究，决定自2025年5月1日起按照各省份对于未中选产品的规则和要求，陆续调整、梯度 降低该药物的市场零售价格，相比此前中标价格降价幅度不低于 35%。 本次价格调整后，预计对该药物2025年第二季度及后续执行期间的销售收入产生不利影响。鉴于该药物 价格调整及本次集采未中选后销售量下滑等因素，预计将导致该药物2025年度销售收入同比下降，其对 本集团实际业绩影响最终以本集团经审计的2025年度财务数据为准。本公司将依据香港联合交易所有限 公司证券上市规则及其他相关规则及规定，及时就本集团的财务表现另行刊发公告。 未来，本公司将继续维持与国内外现有主要供应商的长期合作;确保生产制造体系团队稳定;强化生产全 过程质量控制。本公司秉持对患者负责的经营理念，将一如既往保障药品质量稳定可靠。 本公司将持续关注省级、直辖市等地方销售政策，继续梳理优化营销网络，研究各省医保政策、商保政 策及招标方案;积极开发空白医疗机构，加强在民营医院、盈利性医疗机构等终端市场的开拓力度，提 升终端服务能力;通过临床疗效数据、患者教育等学术推广等方式强化产品差异化优势，提升品牌影响 力。 本集团将持续加大研发投入，加速研发项目 ...

Group 1 - ST Xinchao is unable to disclose its audited annual report for 2024 and Q1 2025 by the legal deadline, leading to a stock suspension starting May 6, 2025. If the report is not disclosed within two months, the stock will face delisting risk warning [3] - Wolong Real Estate plans to change its stock name to "Wolong New Energy" to align with national "dual carbon" policies and to explore new profit growth points in the renewable energy sector [4] - Dongzhu Ecology clarifies that it only holds a 10% stake in Dilos AI Technology and has no substantial business cooperation with it, as Dilos is still in its early stages of development [5] Group 2 - Haitian Flavor Industry has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue up to 710.52 million shares for listing on the Hong Kong Stock Exchange, though uncertainties remain [6] - Jiawei New Energy's controlling shareholder received a warning letter from the Shenzhen Securities Regulatory Bureau for failing to fulfill a commitment to increase shareholding by at least 60 million yuan [7] - Fudan Zhangjiang will reduce the market retail price of its Doxorubicin Liposome Injection by no less than 35% starting May 1, 2025, which may negatively impact its sales revenue and lead to potential losses for this product in 2025 [8] Group 3 - Tongguang Cable is a pre-selected candidate for two procurement projects from the State Grid Corporation, with a total expected bid amount of 142 million yuan, representing approximately 5.49% of the company's total revenue for 2024 [12]

股票代码：688505 股票简称：复旦张江 编号：临 2025-016 上海复旦张江生物医药股份有限公司 关于药品价格调整的公告 1 经公司审慎研究，决定自 2025 年 5 月 1 日起按照各省份对于未中选产品的 规则和要求，陆续调整、梯度降低该药物的市场零售价格，相比此前中标价格降 价幅度不低于 35%。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、药品的基本情况 本公司纳米技术平台抗肿瘤药物盐酸多柔比星脂质体注射液（商标名：里葆 多®）（以下简称"该药物"）于 2009 年 8 月上市销售，为楷莱®（即 Doxil®/Caelyx ®） 的国内首仿药，是国内外首个纳米药物的仿制药物。该药物是一种采用先进的隐 形脂质体技术包封，具有被动靶向特性的多柔比星新剂型，它是蒽环类药物的更 新换代产品，在肿瘤治疗学上具有提高疗效、降低心脏毒性、骨髓抑制以及减少 脱发等优势。该药物主要用于与艾滋病相关的卡波氏肉瘤，亦可用于多发性骨髓 瘤、乳腺癌和卵巢癌等肿瘤的治疗。 2024 年度，该药物销售收入约为人民币 2.1 亿元， ...

Core Viewpoint - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting from May 1, 2025, which is expected to negatively impact the company's sales revenue in 2025 and beyond [1] Group 1: Company Impact - The Doxorubicin Liposome Injection generated approximately RMB 210 million in sales revenue for the year 2024, accounting for 29% of the company's total annual sales revenue [1] - The price adjustment is anticipated to lead to a potential single-product loss for the Doxorubicin Liposome Injection in 2025 [1] Group 2: Market Implications - The decision to lower the price reflects the company's strategy to remain competitive in the market, but it poses risks to future revenue streams [1]

国泰海通证券股份有限公司 关于上海复旦张江生物医药股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为上海复 旦张江生物医药股份有限公司（以下简称"复旦张江"、"公司"或"发行人"）首次 公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交 易所科创板股票上市规则》等有关法律法规和规范性文件的要求，就复旦张江使 用暂时闲置募集资金进行现金管理的事项进行了审慎核查，并发表如下核查意 见: 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海复旦张江生物医药股份有限公司 首次公开发行股票注册的批复》（证监许可〔2020〕912 号）同意批复，公司公 开发行人民币普通股 12,000 万股，发行价格为人民币 8.95 元/股，募集资金总额 为人民币 107,400.00 万元，扣除发行费用人民币 9,967.61 万元，募集资金净额为 人民币 97,432.39 万元。 ...

股票代码：688505 股票简称：复旦张江 编号：临 2025-014 上海复旦张江生物医药股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好、有保本约定的投资产品（包括但不限 于购买保本型理财产品、结构性存款、大额存单、定期存款、通知存款等）。 投资金额及期限：上海复旦张江生物医药股份有限公司（以下简称"公 司"或"本公司"）使用额度不超过人民币18,000万元（包含本数）的暂时闲置 募集资金进行现金管理，使用期限自2025年6月20日起12个月之内有效。在前述 额度及使用期限范围内，资金可以循环滚动使用。 已履行的审议程序：公司于2025年4月28日召开第八届董事会第十次会议、 第八届监事会第九次会议，分别审议通过了《关于使用暂时闲置募集资金进行现 金管理的议案》，公司保荐机构国泰海通证券股份有限公司（以下简称"保荐机 构"）对上述事项出具了明确的核查意见。 特别风险提示：本次现金管理方式是安全性高、流动性好、保本型的理 ...

上海复旦张江生物医药股份有限公司 2024 年度股东周年大会 会议资料 二〇二五年六月 | 目录 | | --- | | 会议须知 | | | 1 | | --- | --- | --- | --- | | 会议议程 | 3 | | | | 会议议案 | 5 | | | | 议案 1：《关于 | 5 2024 | 年度董事会（工作）报告的议案》 | | | 议案 2：《关于 | 2024 11 | 年度监事会（工作）报告的议案》 | | | 议案 | 股年度报告及摘要；及 股经 A H | 3：《关于本公司截至二零二四年十二月三十一日止 | | | | 审计的财务报表及核数师报告的议案》 14 | | | | 议案 4：《关于 | 15 2024 | 年度财务决算报告的议案》 | | | 议案 5：《关于 | 2024 17 | 年度利润分配预案的议案》 | | | 议案 6：《关于续聘 | 19 | 年度境内外会计师事务所的议案》 2025 | | | 议案 7：《关于公司 | 2025 年度薪酬方案的议案》 20 | 2024 年度董事、监事薪酬执行情况及 | | | 议案 | 8：《关于提请股东大会授权 ...